drugset / Trial / NCT00479622
Study of TRU-015 in Subjects With Membranous Nephropathy Secondary to Systemic Lupus Erythematosus
Phase 1
Terminated
20 enrolled
Wyeth is now a wholly owned subsidiary of Pfizer
Emergent Product Development Seattle LLC · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine how the body absorbs and chemically changes a single infusion of TRU-015 in subjects with kidney disease caused by lupus.
Timeline
- Start
- 2007-08
- Primary completion
- 2008-05
- Completion
- 2008-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TRU-015 | Unknown | 800 mg | — |
| Subject | TRU-015 | Unknown | 2000 mg | — |